Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 17 of 1,261
  1. US 12403196

    Ras inhibitors

    Revolution Medicines, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  2. US 12404328

    Multi-specific binding proteins and methods of use thereof

    Cullinan Management, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  3. US 12403087

    Topical antiviral compositions, delivery systems, and methods of using the same

    Ligand Pharmaceuticals Incorporated Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  4. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  5. US 12403141

    Deuterated MK2 pathway inhibitors and methods of using the same

    Aclaris Therapeutics, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  6. US 12403192

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  7. US 12404347

    Glucuronoxylomannan (GXM) receptor chimeric antigen receptors and use thereof

    The Board of Regents of the University of Texas System Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  8. US 12404227

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  9. US 12403134

    Method for improving or enhancing cognition

    VANDA PHARMACEUTICALS INC. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  10. US 12403137

    Compounds and methods of use

    Tango Therapeutics, Inc. Β· Granted Sep 2, 2025 Β· Expires Aug 28, 2045

    granted
  11. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  12. US 12398131

    Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof

    IDEAYA Biosciences, Inc. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  13. US 12398179

    Nanomolar peptides and derivatives to differentially modulate ephrin receptors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  14. US 12398123

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    United States Government as represented by the Department of Veterans Affairs Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  15. US 12397058

    Metabolically stable prodrugs

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  16. US 12398194

    Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

    AUTOLUS LIMITED Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  17. US 12396974

    Ketone ester as a therapeutic treatment of Covid-19 and related viral infections

    KetoneAid Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  18. US 12398375

    Methods for improved poxvirus yields

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  19. US 12397028

    Adoptive cellular therapy

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  20. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  21. US 12396989

    Nicorandil derivatives

    UNICYCIVE THERAPEUTICS, INC. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  22. US 12396988

    Methods of using muscarinic antagonists in the treatment of depression

    The Board of Regents of the University of Texas System Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  23. US 12396991

    Biomarkers for the diagnosis and treatment of fibrotic lung disease

    The Regents of the University of Colorado, a Body Corporate Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted
  24. US 12396952

    Tuning of release kinetics in hydrogels

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 26, 2025 Β· Expires Aug 21, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.